Phase 4 N=100 Randomized Quadruple-blind Prevention

Dexamethasone vs Ondansetron After Cesarean Delivery

Nausea and Vomiting, Postoperative · Cesarean Section Complications

Bottom Line

View on ClinicalTrials.gov: NCT05692245 ↗

Enrolled (actual)

100

Serious AEs

0.0%

Results posted

Mar 2026

Primary outcome: Primary: Medications Received — 0.23; 0.40 Medications

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Ondansetron (Drug); Dexamethasone (Drug)
Age: Adult · 18+ yrs
Sex: Female
Sponsor: Beth Israel Deaconess Medical Center
Primary completion: Apr 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Medications Received	0.23; 0.40	—
SECONDARY Severity of Nausea	0; 0	—
SECONDARY Severity of Pain	3; 2.7	—

Summary

The goal of this clinical trial is to compare medications in women having a cesarean delivery. The main question it aims to answer are: • Which medication is better to use as a first-line prevention agent for nausea and vomiting Participants will rate their nausea, pain and other symptoms after surgery Researchers will compare two drugs, ondansetron and dexamethasone to see if the side effects of pain medications are improved after cesarean.

Eligibility Criteria

Inclusion Criteria

Healthy women (ASA 2)
Between 18 and 45 years old
Singleton term pregnancies
Scheduled or non-labor cesarean delivery
Neuraxial (spinal or combined-spinal epidural) anesthesia

Exclusion Criteria

Refusal to participate
Known allergy or contraindication to any medication used in the study
Significant medical or obstetrical disease (ASA ≥ 3)
Antiemetic use within 24 hours preceding cesarean delivery
Insulin dependent diabetes
Hyperemesis gravidarum or chronic antiemetic use
History of daily or near-daily steroid use during pregnancy
Opioid use disorder or other chronic pain syndrome
Opioid use during pregnancy
Use of antipruritus medication, pruritic urticarial papules of pregnancy, or cholestasis of pregnancy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05692245). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.